<DOC>
	<DOC>NCT00365378</DOC>
	<brief_summary>Subjects received HPV 16 L1 VLP vaccine or placebo (1:1 ratio). Endpoints included efficacy, immunogenicity, and safety.</brief_summary>
	<brief_title>Study of Human Papillomavirus (HPV) 16 Vaccine in the Prevention of HPV 16 Infection in 16- to 23-Year-Old Females (V501-005)</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Healthy, unmarried females age 16 to 23 years with intact uteri Not pregnant at enrollment Agreed to use effective contraception through Month 7 of the study A lifetime history of 0 to 5 male partners with whom the subjects engaged in at least one episode of insertive intercourse No prior history of Human Papillomavirus (HPV) vaccination No receipt of any other vaccination within 1 month prior to enrollment or plans to receive any other vaccination within 1 month prior to or after any dose of study vaccine No prior history of an abnormal Papanicolaou (Pap) test showing Squamous intraepithelial lesion (SIL) or biopsy showing Cervical intraepithelial neoplasia (CIN)</criteria>
	<gender>Female</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>23 Years</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>